To assess the
clinical efficacy of
Chinese patent medicine for
bradyarrhythmia(BA) by using
network Meta-analysis method. Relevant randomized controlled trials(RCTs) of
Chinese patent medicine for BA were retrieved from
China National
Knowledge Infrastructure(CNKI), WanFang Database, VIP database, SinoMed,
PubMed and Cochrane
Library. The retrieval
time ranged from the commencement of each database to February 2019. We completed the
literature screening and data extraction according to the pre-determined inclusion and exclusion criteria. The quality of inclusion studies was assessed using the
bias risk assessment tool recommended by the Cochrane
Handbook of
Systematic Review 5.3. The data were analyzed by WinBUGS, and STATA
software was used for plotting. Finally, 46 RCTs were included, involving 4
Chinese patent medicines and 3 306
patients. According to the
network Meta-analysis, the total effective rate in alleviating BA symptoms had 7 direct comparisons and 3 indirect comparisons. The
efficacy of the 4
Chinese patent medicines combined with routine
therapy was superior to that of routine
therapy, with statistically significant differences. The order of the four
Chinese patent medicines by
efficacy was as follows Shenxian Shengmai Oral Liquid>Shensong Yangxin
Capsules>Xinbao Pills>Ningxinbao
Capsules. The average
heart rate had 7 direct comparisons and 3 indirect comparisons. The
efficacy of Shenxian Shengmai Oral Liquid and Shensong Yangxin
Capsules combined with routine
therapy was superior to that of routine
therapy, with statistically significant differences. The order of the four
Chinese patent medicines by
efficacy was as follows Shenxian Shengmai Oral Liquid>Shensong Yangxin
Capsules>Xinbao Pills>Ningxinbao
Capsules. The results showed that the
Chinese patent medicines combined with routine
therapy were effective in the
treatment of BA. Due to the differences in the quantity and quality of the included studies on different
Chinese patent medicines, the sequencing results of
Chinese patent medicines need to be further verified.